Page 11234..1020..»

Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference

By Dr. Matthew Watson

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 44th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), which will be held virtually February 20–24, 2021.

See the rest here:
Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference

To Read More: Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference
categoriaGlobal News Feed commentoComments Off on Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference | dataFebruary 19th, 2021
Read All

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

By Dr. Matthew Watson

CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:

Original post:
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

To Read More: Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Fulcrum Therapeutics to Participate in Upcoming Investor Conferences | dataFebruary 19th, 2021
Read All

Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021

By Dr. Matthew Watson

SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it will present updated interim data from its REPAIR-MS study and updated blinded interim data from its VISIONARY-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis’ ACTRIMS Forum 2021 (“ACTRIMS”) taking place virtually from February 25-27, 2021.

Go here to read the rest:
Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021

To Read More: Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021
categoriaGlobal News Feed commentoComments Off on Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021 | dataFebruary 19th, 2021
Read All

BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report®

By Dr. Matthew Watson

SANTA MONICA, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced an interview with Terren Peizer, Chairman and Chief Executive Officer, will air on The RedChip Money Report® on Bloomberg TV in the US on Saturday, February 20, at 7 p.m. local time in 73M homes across the United States. The RedChip Money Report® also airs on Bloomberg International in Europe in 100M homes at 6 pm local time on Sundays.

See original here:
BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report®

To Read More: BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
categoriaGlobal News Feed commentoComments Off on BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report® | dataFebruary 19th, 2021
Read All

Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference

By Dr. Matthew Watson

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, from 1:40-2:10 p.m. ET.

Follow this link:
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference

To Read More: Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference | dataFebruary 19th, 2021
Read All

Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol…

By Dr. Matthew Watson

Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy

Read more:
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol...

To Read More: Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol…
categoriaGlobal News Feed commentoComments Off on Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol… | dataFebruary 19th, 2021
Read All

BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i…

By Dr. Matthew Watson

SAN FRANCISCO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO),?a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers,?and affiliate ML Bio Solutions today announced that the first patient has been dosed in a Phase 2 trial of BBP-418 in patients with LGMD2i. BridgeBio and ML Bio’s BBP-418 is the first-ever oral disease-modifying investigational treatment for LGMD2i. BBP-418 was granted Orphan Drug Designation for LGMD2i by the US Food and Drug Administration (FDA) in 2019, and for LGMD by the European Medicines Agency (EMA) in 2020.

Original post:
BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i...

To Read More: BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i…
categoriaGlobal News Feed commentoComments Off on BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i… | dataFebruary 19th, 2021
Read All

Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA

By Dr. Matthew Watson

NEW YORK and MAINZ, GERMANY, February 19, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the submission of new data to the U.S. Food and Drug Administration (FDA) demonstrating the stability of their COVID-19 vaccine when stored at -25°C to -15°C (-13°F to 5°F), temperatures more commonly found in pharmaceutical freezers and refrigerators. The data have been submitted to the FDA to support a proposed update to the U.S. Emergency Use Authorization (EUA) Prescribing Information, which would allow for vaccine vials to be stored at these temperatures for a total of two weeks as an alternative or complement to storage in an ultra-low temperature freezer.

Visit link:
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA

To Read More: Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
categoriaGlobal News Feed commentoComments Off on Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA | dataFebruary 19th, 2021
Read All

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates

By Dr. Matthew Watson

CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, February 26, 2021 at 8:00 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2020 and provide business updates.

Read more:
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates

To Read More: Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates
categoriaGlobal News Feed commentoComments Off on Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates | dataFebruary 19th, 2021
Read All

Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform

By Dr. Matthew Watson

Partnerships will use Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery Partnerships will use Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery

See the rest here:
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform

To Read More: Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform
categoriaGlobal News Feed commentoComments Off on Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform | dataFebruary 19th, 2021
Read All

Assembly Bio Announces Upcoming Investor Events

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced two upcoming investor events:

Read the original post:
Assembly Bio Announces Upcoming Investor Events

To Read More: Assembly Bio Announces Upcoming Investor Events
categoriaGlobal News Feed commentoComments Off on Assembly Bio Announces Upcoming Investor Events | dataFebruary 19th, 2021
Read All

Intercept to Present at Upcoming Investor Conferences

By Dr. Matthew Watson

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer, and Sandip Kapadia, Chief Financial Officer of Intercept, will present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 1:00 p.m. ET, and at the Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021 at 10:30 a.m. ET.

See the original post:
Intercept to Present at Upcoming Investor Conferences

To Read More: Intercept to Present at Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Intercept to Present at Upcoming Investor Conferences | dataFebruary 19th, 2021
Read All

RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 12:00 pm Eastern Time.

See more here:
RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

To Read More: RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference | dataFebruary 19th, 2021
Read All

Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million

By Dr. Matthew Watson

WOBURN, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has received proceeds of approximately $3.8 million from the exercise of 472,099 warrants exercised between January 1, 2021 and February 16, 2021, and the Company has issued to investors 472,099 shares of common stock in exchange for the exercised warrants. The warrants were issued to investors pursuant to a public offering that closed on November 19, 2019. Since November 19, 2019, a total of 679,395 warrants issued in the public offering have been exercised for total proceeds of $5.4 million. The Series A and Series B warrants issued in the November 2019 public offering are exercisable at $8.00 per share and have expiration dates of May 19, 2022 and May 19, 2027, respectively.

View original post here:
Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million

To Read More: Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million
categoriaGlobal News Feed commentoComments Off on Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million | dataFebruary 19th, 2021
Read All

CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology

By Dr. Matthew Watson

MIAMI, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, Chief Executive Officer of Longeveron, has been invited to give a presentation titled “A Regenerative Medicine Approach to Aging Frailty” at the Intercontinental Summit on Aging & Gerontology being held virtually on March 8, 2021. He will discuss Longeveron’s ongoing clinical research program in Aging Frailty and Alzheimer’s disease, in addition to the regenerative medicine investigational clinical research field in general for diseases and conditions associated with aging.

See the original post here:
CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology

To Read More: CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology
categoriaGlobal News Feed commentoComments Off on CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology | dataFebruary 19th, 2021
Read All

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

By Dr. Matthew Watson

Chugai obtains exclusive development and marketing rights for AT-527 in Japan from Roche, who has ex-US rights for the treatment of COVID-19 Chugai obtains exclusive development and marketing rights for AT-527 in Japan from Roche, who has ex-US rights for the treatment of COVID-19

See original here:
Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

To Read More: Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan
categoriaGlobal News Feed commentoComments Off on Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan | dataFebruary 19th, 2021
Read All

Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on…

By Dr. Matthew Watson

Live Conference Call and Webcast at 4:30 p.m. ET

View original post here:
Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on...

To Read More: Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on…
categoriaGlobal News Feed commentoComments Off on Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on… | dataFebruary 19th, 2021
Read All

Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021

By Dr. Matthew Watson

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the fiscal year ended December 31, 2020 on Thursday, February 25, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, February 26, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.

Here is the original post:
Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021

To Read More: Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021
categoriaGlobal News Feed commentoComments Off on Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 | dataFebruary 19th, 2021
Read All

Information expressed in the public domain by the Repharm Group is deceptive and contradictory

By Dr. Matthew Watson

Today, on February 19, information has arrived in the public domain that the company from Repharm Group will acquire the shares of JSC “Olainfarm” directly and indirectly owned by Anna Emilija Maligina.

Visit link:
Information expressed in the public domain by the Repharm Group is deceptive and contradictory

To Read More: Information expressed in the public domain by the Repharm Group is deceptive and contradictory
categoriaGlobal News Feed commentoComments Off on Information expressed in the public domain by the Repharm Group is deceptive and contradictory | dataFebruary 19th, 2021
Read All

Ayala Pharmaceuticals Announces $25 Million Strategic Financing

By Dr. Matthew Watson

Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023

Read more:
Ayala Pharmaceuticals Announces $25 Million Strategic Financing

To Read More: Ayala Pharmaceuticals Announces $25 Million Strategic Financing
categoriaGlobal News Feed commentoComments Off on Ayala Pharmaceuticals Announces $25 Million Strategic Financing | dataFebruary 19th, 2021
Read All

Page 11234..1020..»